LAS VEGAS, Jan. 5, 2016 /PRNewswire/ -- GrowBLOX Sciences, Inc., (OTCQB: GBLX), The Company is proud to announce the appointment of Mr. John Poss as its President and Chief Operating Officer. John joined the Company earlier this year as a consultant, and became Chief Financial Officer during the summer, and, as was previously announced, has extensive executive experience in both finance and operations for an enviable group of industrial enterprises, both large and small. For the moment, Mr. Poss will retain both the chief operating and chief financial titles.
Chairman Craig Ellins said "John has already taken over most of the financial and operational duties of the company, leaving me free to develop the pharmaceutical/science side with our team of PhD level employees and consultants. Since we expect the Company to have significant revenues commencing in 2016, an efficient operations officer like John will assure that we maximize the potential of all of the licenses that we have been granted, and will keep the proper focus on the simple and straightforward progress which is all that is necessary, from this point on, to generate substantial revenue and earnings."
The Company is also proud to announce the appointment of Ms. Ksenia Griswold, CPA, as the Company's new Controller. Ksenia comes to us from Ernst & Young here in Las Vegas, where she was a highly regarded Manager.
President John Poss said "We consider ourselves quite fortunate to find someone as skilled and as organizationally astute as Ksenia. She is a congenial and expertised addition to our management team, and among her other extraordinary accomplishments, she achieved one of the top 10 scores in the Nevada CPA exam in 2010. We are quite certain that Ksenia will establish the best practices and crisp reporting that are essential for a public company in our highly regulated business."
About GrowBLOX Sciences, Inc.
GrowBLOX Sciences, Inc. (GBLX) is a biopharmaceutical research and development company focused on creating safe, standardized, pharmaceutical-grade, cannabinoid therapies that target a variety of medical conditions. The Company has leading technology and cannabis industry processes, with a "big" data-driven clinical research and development loop to bring relief to patients in communities across the country. Through our GBS PR subsidiary, we are developing and globally distributing our GrowBLOX ™ suite of cultivation and growing chambers. To learn more about GrowBLOX Sciences, Inc., go to: http://growblox.com
This press release may contain statements relating to future results or events, which are forward-looking statements. Words such as "expects", "intends", "plans", "may", "could", "should", "anticipates", "likely", "believes" and words of similar import may identify forward-looking statements. These statements are not historical facts, but instead represent only the Company's belief regarding future events, many of which, by their nature, are inherently uncertain and outside of the Company's control. It is possible that the Company's actual results and financial condition may differ, possibly materially, from the anticipated results and financial condition indicated in these forward-looking statements. Further, information concerning the Company and its business, including factors that potentially could materially affect the Company's business and financial and other results, are contained in the Company's filings with the Securities and Exchange Commission, available at www.sec.gov. All forward-looking statements included in this press release are made only as of the date of this press release, and we do not undertake any obligation to publicly update or correct any forward-looking statements to reflect events or circumstances that subsequently occur or of which we hereafter become aware.
Note: Although the Company's research and development activities are not illegal, the production and sale of cannabis products violate federal laws as they presently exist.
GrowBLOX is a registered trademark of GrowBLOX Sciences, Inc.
SOURCE GrowBLOX Sciences, Inc.